Rare
lephants
Screener
Toggle theme
Royalty Pharma plc
RPRX
·
Healthcare, Drug Manufacturers - General, United States
Financial Statements
Profitability
Balance Sheet
Cash Flow
Price Ratios
Share-Based Metrics
Valuation
Cash Flow History
Net Cash Flow Breakdown
Net Cash Flow
Cash Flow
›
Net Cash Flow Breakdown
Net Cash Flow Breakdown
Chart
Table
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Total Cash from Operations:
$2.35B
Line Item
Value
% of Total
Other Investing
$1.07B
45.7%
Stock Repurchases
$4.3M
0.2%
Other Financing
$589.6M
25.1%
Working Capital
$681.3M
29.0%
Net Cash Flow
$0
0.0%
Download CSV
